Published in Proc Natl Acad Sci U S A on August 20, 2012
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov (2014) 1.39
Vaccines for the 21st century. EMBO Mol Med (2014) 1.17
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect (2013) 1.04
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release (2015) 0.97
A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther (2014) 0.92
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett (2015) 0.86
mRNA capping: biological functions and applications. Nucleic Acids Res (2016) 0.86
The history of vaccination against cytomegalovirus. Med Microbiol Immunol (2015) 0.86
Recent advances in the molecular design of synthetic vaccines. Nat Chem (2015) 0.85
Recent Developments in Preclinical DNA Vaccination. Vaccines (Basel) (2014) 0.85
Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol (2013) 0.84
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J Virol (2015) 0.83
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis (2014) 0.83
RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm (2013) 0.83
Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale (2014) 0.83
Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine (2014) 0.82
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther (2016) 0.81
Vaccines against respiratory syncytial virus: The time has finally come. Vaccine (2016) 0.81
Viral and Synthetic RNA Vector Technologies and Applications. Mol Ther (2016) 0.80
Antiviral regulation in porcine monocytic cells at different activation states. J Virol (2014) 0.79
Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines. J Immunol Res (2015) 0.79
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ. Vaccines (Basel) (2013) 0.79
Engineered biomaterials for development of nucleic acid vaccines. Biomater Res (2015) 0.79
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79
Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int (2014) 0.79
Alphaviruses in gene therapy. Viruses (2015) 0.79
CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology (2015) 0.78
Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. J Immunol Methods (2015) 0.78
Delivering vaccines to the people who need them most. Philos Trans R Soc Lond B Biol Sci (2015) 0.77
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A (2016) 0.77
RNA-based vaccination: sending a strong message. Mol Ther (2013) 0.76
Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine? Nat Rev Drug Discov (2012) 0.76
Cytomegalovirus Vaccines: Current Status and Future Prospects. Drugs (2016) 0.76
Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design. J Immunol (2017) 0.75
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther (2017) 0.75
Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS One (2016) 0.75
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. J Immunother Cancer (2015) 0.75
Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP). Front Microbiol (2017) 0.75
Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles. Vaccines (Basel) (2014) 0.75
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun (2017) 0.75
Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials (2016) 0.75
An in silico approach to design potential siRNA molecules for ICP22 (US1) gene silencing of different strains of human herpes simplex 1. J Young Pharm (2013) 0.75
Lipid nanoparticle-based delivery of RNA. Nanomedicine (Lond) (2013) 0.75
Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Digital-to-biological converter for on-demand production of biologics. Nat Biotechnol (2017) 0.75
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med (1993) 5.67
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol (1985) 2.87
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release (2005) 2.47
Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 2.04
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother (2011) 2.01
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res (2005) 1.83
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 1.83
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine (2009) 1.65
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol (2000) 1.48
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol (2007) 1.42
Alphavirus vectors and vaccination. Rev Med Virol (2002) 1.40
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40
mRNA as gene therapeutic: how to control protein expression. J Control Release (2010) 1.40
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol (1993) 1.29
Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci U S A (2004) 1.23
A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res (1995) 1.20
Messenger RNA-based vaccines. Expert Opin Biol Ther (2004) 1.18
Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol (2008) 1.17
Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med (2008) 1.07
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis (2001) 1.07
Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther (1999) 1.07
Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther (2006) 1.01
RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses (2010) 0.97
Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One (2012) 0.96
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol Ther (2010) 0.95
mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines (2012) 0.92
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol (2007) 0.89
Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques (2007) 0.87
Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol Med Rep (2011) 0.84
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Near-atomic resolution using electron cryomicroscopy and single-particle reconstruction. Proc Natl Acad Sci U S A (2008) 5.33
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
RNA interference screen for human genes associated with West Nile virus infection. Nature (2008) 4.93
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
West Nile virus: where are we now? Lancet Infect Dis (2004) 3.49
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest (2006) 3.31
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Analysis of changing paradigms of management in 179 patients with spinal tuberculosis over a 12-year period and proposal of a new management algorithm. World Neurosurg (2013) 2.94
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat Cell Biol (2006) 2.83
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Molecular interactions in rotavirus assembly and uncoating seen by high-resolution cryo-EM. Proc Natl Acad Sci U S A (2009) 2.65
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 2.63
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem (2005) 2.36
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine (2006) 1.99
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol (2003) 1.90
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis. J Virol (2007) 1.86
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Atomic model of an infectious rotavirus particle. EMBO J (2010) 1.79
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 1.78
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. Am J Hum Genet (2006) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science (2009) 1.66
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A (2007) 1.64
Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov (2003) 1.60
West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment. Virology (2005) 1.59
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol (2003) 1.59
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
trans-Packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors. J Virol (2004) 1.57
Phylogeny of the SARS coronavirus. Science (2003) 1.56
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54
Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine (2008) 1.54
Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology (2008) 1.54
West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J Virol (2007) 1.54